61453-48-3

Basic information

• Product Name: ethyl 5-(hydroxymethyl)-1H-pyrazole-3-carboxylate
• Synonyms: ethyl 5-(hydroxymethyl)-1H-pyrazole-3-carboxylate;Ethyl 5-(HydroxyMethyl)pyrazole-3-carboxylate;5-(hydroxymethyl)-1H-Pyrazole-3-carboxylic acid ethyl ester
• CAS NO: 61453-48-3
• Molecular Formula: C7H10N2O3
• Molecular Weight: 170
• Mol File: 61453-48-3.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Store in freezer, under -20°C
• CAS DataBase Reference: ethyl 5-(hydroxymethyl)-1H-pyrazole-3-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 5-(hydroxymethyl)-1H-pyrazole-3-carboxylate(61453-48-3)
• EPA Substance Registry System: ethyl 5-(hydroxymethyl)-1H-pyrazole-3-carboxylate(61453-48-3)

Safety Data

• Hazardous Substances Data: 61453-48-3(Hazardous Substances Data)

Usage

General Description

Ethyl 5-(hydroxymethyl)-1H-pyrazole-3-carboxylate is a chemical compound with the molecular formula C8H12N2O4. It is a derivative of pyrazole, containing an ethyl ester group, a carboxylic acid group, and a hydroxymethyl group. ethyl 5-(hydroxymethyl)-1H-pyrazole-3-carboxylate has potential applications in organic synthesis and pharmaceutical research. It may also have biological activity due to its structural similarity to other pyrazole derivatives, which are known to have various pharmacological properties. Due to its specific structure and properties, ethyl 5-(hydroxymethyl)-1H-pyrazole-3-carboxylate has the potential to be utilized in a range of scientific and industrial applications.

Upstream product

• 623-73-4 diazoacetic acid ethyl ester 
• 107-19-7 propargyl alcohol 
• 71-43-2 benzene 

Downstream Products

• 71083-83-5 5-hydroxymethyl-1(2)H-pyrazole-3-carboxylic acid amide 
• 1401555-38-1 5-hydroxymethyl-1⁽²⁾H-pyrazole-3-carboxylic acid 

Relevant articles and documents

-

-

BICYCLIC KETONE COMPOUNDS AND METHODS OF USE THEREOF

The invention provides novel compounds having the general formula (I): (I) wherein R1, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.

Agonist lead identification for the high affinity niacin receptor GPR109a

A strategy for lead identification of new agonists of GPR109a, starting from known compounds shown to activate the receptor, is described. Early compound triage led to the formulation of a binding hypothesis and eventually to our focus on a series of pyrazole acid derivatives. Further elaboration of these compounds provided a series of 5,5-fused pyrazoles to be used as lead compounds for further optimization.